» Articles » PMID: 34439094

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Aug 27
PMID 34439094
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Efficient treatment of disseminated ovarian cancer (OC) is challenging due to its heterogeneity and chemoresistance. Overexpression of human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM) in approx. 30% and 70% of ovarian cancers, respectively, allows for co-targeted treatment. The clinical efficacy of the monoclonal antibody trastuzumab in patients with HER2-positive breast, gastric and gastroesophageal cancers makes it readily available as the HER2-targeting component. As the EpCAM-targeting component, we investigated the designed ankyrin repeat protein (DARPin) Ec1 fused to a truncated variant of Pseudomonas exotoxin A with reduced immunogenicity and low general toxicity (LoPE). Ec1-LoPE was radiolabeled, evaluated in ovarian cancer cells in vitro and its biodistribution and tumor-targeting properties were studied in vivo. The therapeutic efficacy of Ec1-LoPE alone and in combination with trastuzumab was studied in mice bearing EpCAM- and HER2-expressing SKOV3 xenografts. SPECT/CT imaging enabled visualization of EpCAM and HER2 expression in the tumors. Co-treatment using Ec1-LoPE and trastuzumab was more effective at reducing tumor growth and prolonged the median survival of mice compared with mice in the control and monotherapy groups. Repeated administration of Ec1-LoPE was well tolerated without signs of hepatic or kidney toxicity. Co-treatment with trastuzumab and Ec1-LoPE might be a potential therapeutic strategy for HER2- and EpCAM-positive OC.

Citing Articles

Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts.

Zhang J, Rinne S, Yin W, Leitao C, Bjorklund E, Abouzayed A ACS Pharmacol Transl Sci. 2024; 7(10):3228-3240.

PMID: 39416966 PMC: 11475273. DOI: 10.1021/acsptsci.4c00402.


HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research.

Hofheinz R, Lorenzen S, Bohlmann M Cancers (Basel). 2023; 15(13).

PMID: 37444443 PMC: 10341063. DOI: 10.3390/cancers15133333.


Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Xu T, Schulga A, Konovalova E, Rinne S, Zhang H, Vorontsova O Int J Mol Sci. 2023; 24(3).

PMID: 36769161 PMC: 9917732. DOI: 10.3390/ijms24032838.


Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc and I.

Tolmachev V, Bodenko V, Orlova A, Schulga A, Deyev S, Vorobyeva A Oncol Lett. 2022; 25(1):12.

PMID: 36478911 PMC: 9713777. DOI: 10.3892/ol.2022.13598.


Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.

Garousi J, Xu T, Liu Y, Vorontsova O, Hober S, Orlova A Pharmaceutics. 2022; 14(8).

PMID: 36015242 PMC: 9415843. DOI: 10.3390/pharmaceutics14081612.


References
1.
Mazor R, Vassall A, Eberle J, Beers R, Weldon J, Venzon D . Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A. 2012; 109(51):E3597-603. PMC: 3529021. DOI: 10.1073/pnas.1218138109. View

2.
Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A . Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer. 2002; 98(6):883-8. DOI: 10.1002/ijc.10270. View

3.
Kondo T, Fitzgerald D, Chaudhary V, Adhya S, Pastan I . Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988; 263(19):9470-5. View

4.
Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Ivanchenko V . The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127(9):2209-21. PMC: 2958458. DOI: 10.1002/ijc.25423. View

5.
Dokmanovic M, Wu W . Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine. Adv Clin Chem. 2015; 70:95-130. DOI: 10.1016/bs.acc.2015.03.006. View